Navigation Links
ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
Date:8/5/2010

ns.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent.  With Cinryze, the risk of transmission of infectious material has been reduced by screening patients for prior exposure to certain virus infections and by manufacturing steps designed to reduce the risk of viral transmission including pasteurization and nanofiltration.

"Due to the lack of awareness about HAE, which is a rare, debilitating and potentially-life threatening disease, patients are often misdiagnosed and undergo unnecessary exploratory surgeries before receiving an accurate diagnosis," said Zuraw, professor of medicine and program director of the Allergy and Immunology Fellowship Program at the University of California at San Diego, and lead author and principal investigator of the study.  "It is vital for healthcare providers to understand the disease and available prophylactic options so HAE patients can be effectively diagnosed and managed.  Our hope is that published data like these, showing the safety and efficacy of an FDA-approved therapy such as Cinryze, will educate physicians and patients about the options now available to help prevent HAE attacks."

Cinryze Prophylaxis Study

According to the authors, the prophylaxis study employed a cross-over design to compare Cinryze with placebo in preventing attacks of angioedema during a 24-week period.  The study consisted of two consecutive 12-week treatment periods during which subjects received prophylactic injections every 3 to 4 days.  Subjects were randomized to receive either Cinryze (1000 U) or placebo during the first period.  During the second period, each subject crossed over to receive whichever study medication he or she had not received during the firs
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... , July 13, 2014  Eli Lilly ... announced results from its non-clinical study in genetically ... version of the beta-amyloid antibody N3pG and beta-secretase ... therapy was more effective in removing clumps of ... that is thought to lead to Alzheimer,s disease ...
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, Inc. ... today announced that the Food and Drug Administration ("FDA"), ... comments on RCP,s Investigational New Drug ("IND") application before ... in the US. Dr. Chris Chapman ... and comments on our IND. When we receive the ...
(Date:7/11/2014)... -- Kindred Hospital Houston Northwest, with Wound Care Specialists, ... new outpatient wound healing center.  The wound healing ... hard to heal wounds. Chronic wounds include diabetic ... leg wounds related to blood flow issues, post-surgical ... wounds which are complex and demonstrate delayed healing. ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2
... April 16 Trubion Pharmaceuticals, Inc. (Nasdaq: ... present data regarding its SCORPION(TM) multispecific therapeutic technology ... Association of Cancer Research (AACR) in Denver, April ... present data demonstrating the selectivity and high potency ...
... April 16 Simbionix, the world,s leading,developer of medical ... LLC for distribution of Simbionix,s simulators and related,products. , ... in Russia, Ukraine and CIS countries and,is one of ... Johnson & Johnson LLC will have exclusive ...
Cached Medicine Technology:Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting 2Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting 3Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries 2
(Date:7/13/2014)... The North American water storage systems market is estimated ... by 2018, at a CAGR of 21.0%, from 2013 to ... rapid pace in North America. The U.S. is experiencing high ... wastewater storage and collection, and the increased spending on modernization ... a healthy rate in Canada, and is rising at a ...
(Date:7/13/2014)... July 13, 2014 Advanced boilers ... the least amount of fossil fuels, produce high-capacity ... Due to increased global warming and climate change ... to reduce harmful gas emissions and pollutants coming ... market in the global advance boilers market., The ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study ... Scanning; 3D rendering; Layout and Animation; Image Reconstruction]: ... 2018)”, which analyzes and studies the major market ... Europe, Eastern Europe, Middle East and Africa, Asia-Pacific ... competitive landscape of the 3D imaging market, providing ...
(Date:7/13/2014)... July 13, 2014 The Pearland, Texas location ... in age from four months to 12 years of age ... classes to birthday parties and Summer Camps, is now under ... Gym of Pearland after spending over six years at ... including Gym Director. , Berry has over ten years ...
(Date:7/13/2014)... July 13, 2014 Recently, 2014QuinceaneraDresses.com, ... has unveiled its new range of gorgeous ... market, the demand for elegant Quinceanera outfits is ... beautiful items. All the company’s newly released dresses ... They are all elegant and vivid. , ...
Breaking Medicine News(10 mins):Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2
... sight, researchers say, , TUESDAY, Sept. 15 (HealthDay News) ... for people who suffer vision loss when the large ... extremely compelling results, because a large, longer-term clinical trial ... vein occlusion could experience a visual improvement with treatment," ...
... of virus may last up to a week , TUESDAY, ... seem to be contagious longer than patients with ordinary seasonal ... what impact the findings will have on health-care experts, recommendations ... to produce relatively mild infections in most people and recovery ...
... a nonprofit organization, and the Dartmouth Psychiatric Research ... of evidence-based practiceshave announced a partnership to develop ... and addiction treatment industries. These resources, including curricula, ... published under a new "Dartmouth PRCHazelden" imprint. ...
... activity patterns may explain why some people are able to ... according to a new study by researchers with The Miriam ... have kept the weight off for several years were shown ... areas of the brain associated with behavioral control and visual ...
... , 78 percent of Americans see pharmaceutical ... Calif., Sept. 15 The Greenlining Institute ( www.greenlining.org ... Consulting Group which shows that Americans are losing confidence in the ... The national poll found that an overwhelming number of poll respondents ...
... , , , ... Sept. 15 The upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference, to ... a backdrop for the presentation of EVEREST registry clinical results of ... the most common type of heart valve insufficiency in the United ...
Cached Medicine News:Health News:People With Swine Flu May Be Contagious Longer Than Thought 2Health News:People With Swine Flu May Be Contagious Longer Than Thought 3Health News:Hazelden and Dartmouth Psychiatric Research Center form publishing partnership 2Health News:Brain's response to seeing food may be linked to weight loss maintenance 2Health News:Survey Finds Overwhelming Majority of Americans Believe Special Interests Hindering Health Care Reform 2Health News:Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009 2Health News:Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009 3Health News:Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009 4
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading....
Inquire...
... IGFBP-3 contains 266 amino acids and is variably ... weight estimates of between 43 and 56 kDa. ... IGF-II with high affinity but do not bind ... structurally characterized at this time, IGFBP-3 has been ...
... handle up to 180'000 tests per year ... plates and is capable of processing up ... All assay steps, from loading of the ... controlled by Windows™-based software. Between 119 (standard ...
Medicine Products: